Literature DB >> 18830132

Chemoablation of metastatic melanoma using intralesional Rose Bengal.

John F Thompson1, Peter Hersey, Eric Wachter.   

Abstract

To study the effects of intralesional Rose Bengal for chemoablation of metastatic melanoma. Twenty-six target lesions in 11 patients with locoregionally recurrent disease were injected with the agent PV-10 (10% w/v Rose Bengal in saline) at a dose of 0.5 ml/cc lesion volume. An additional 28 untreated lesions were observed for potential bystander effect. The treatment was well tolerated and an objective response was observed in 12 target lesions, with an additional seven lesions remaining static over at least 12 weeks of observation. In this dose-evaluation study, response rate was dose dependent, increasing to 69% after higher dose injections. Nontarget lesions exhibited a 27% objective response rate that increased to 44% in patients exhibiting a positive response of target lesions. These findings indicate that intralesional Rose Bengal is nontoxic and could benefit patients with metastatic melanoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18830132     DOI: 10.1097/CMR.0b013e32831328c7

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  43 in total

1.  Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.

Authors:  Daniel E Spratt; Elizabeth A Gordon Spratt; Shenhong Wu; Antonio DeRosa; Nancy Y Lee; Mario E Lacouture; Christopher A Barker
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

Review 2.  Regional therapies for locoregionally advanced and unresectable melanoma.

Authors:  Evan S Weitman; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-05-08       Impact factor: 5.150

Review 3.  Current treatment of locoregional recurrence of melanoma.

Authors:  Malcolm Hart Squires; Keith A Delman
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 4.  Advances in the development of intralesional therapies for melanoma.

Authors:  Daniel Y Wang; Douglas B Johnson
Journal:  Melanoma Manag       Date:  2016-11-29

Review 5.  Subcutaneous metastases from melanoma: a discussion of clinical experience.

Authors:  Piotr Rutkowski; Marcin Zdzienicki; Katarzyna Kozak
Journal:  Melanoma Manag       Date:  2014-09-05

Review 6.  Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.

Authors:  Mark B Faries
Journal:  Crit Rev Oncog       Date:  2016

Review 7.  Novel Targets for the Treatment of Melanoma.

Authors:  Lara Ambrosi; Shaheer Khan; Richard D Carvajal; Jessica Yang
Journal:  Curr Oncol Rep       Date:  2019-11-06       Impact factor: 5.075

Review 8.  Intratumoral Immunotherapy-Update 2019.

Authors:  Omid Hamid; Rubina Ismail; Igor Puzanov
Journal:  Oncologist       Date:  2019-11-29

Review 9.  Progression of cutaneous melanoma: implications for treatment.

Authors:  Stanley P L Leong; Martin C Mihm; George F Murphy; Dave S B Hoon; Mohammed Kashani-Sabet; Sanjiv S Agarwala; Jonathan S Zager; Axel Hauschild; Vernon K Sondak; Valerie Guild; John M Kirkwood
Journal:  Clin Exp Metastasis       Date:  2012-08-15       Impact factor: 5.150

10.  Selective toxicity of rose bengal to ovarian cancer cells in vitro.

Authors:  Steven B Koevary
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.